



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville MD 20857

October 23, 2006

Mr. H. Keeto Sabharwal  
Blank Rome, LLP  
600 New Hampshire Ave., NW  
Washington, D.C. 20037

Dear Mr. Sabharwal:

This is a correction to our acknowledgement letter of October 18. It contained a typographical error.

Your petition submitted on behalf of Generamedix Pharmaceuticals, Inc, requesting the Food and Drug Administration to deny the request for reconsideration of the date of approval of Angiomax, was received by this office on 10/18/2006. It was assigned docket number 2001E-0213/CP 1 and it was filed on 10/18/2006. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Gloria Ortega, Deputy Director  
Division of Dockets Management  
Office of Management Programs  
Office of Management

2001E-0213

CR1